

September 22, 2020

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400 001 Scrip Code: 512529	National Stock Exchange of India Limited Listing Department Exchange Plaza, Bandra-Kurla Complex Bandra (East) Mumbai – 400 051 Symbol: SEQUENT
--	---

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Consolidation of shareholding in Provet Veteriner Urunleri San. Ve Tic. A. S., Turkey (Provet) and to make Provet a wholly owned subsidiary of the Company

We refer to our announcement dated August 12, 2020 on the proposed acquisition of minority stake of 40% in Provet through Alivira Animal Health Limited, Ireland, wholly owned subsidiary of the Company and the outcome of Postal Ballot Results dated September 18, 2020 filed with the Stock Exchanges intimating receipt of Shareholders approval for the proposed acquisition.

Further to the above, please find attached disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 consequent to entering into definitive agreement with Dr. Huseyin Aydin for the acquisition of 40% stake from him in Provet.

The said transaction is expected to be completed on or before October 31, 2020.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For **Sequent Scientific Limited**



Krunal Shah

Company Secretary & Compliance Officer



SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No	Particulars	
1.	Name of the Target entity, details in brief such as size, turnover etc.	<p>Name of the Target Company:</p> <p>PROVET VETERINER URUNLERI SAN.VE TIC.A.S. ("Provet"), Turkey</p> <p>Details of Target Company:</p> <p>Provet is amongst the top 3 and the largest local Company in veterinary medicines market in Turkey having market share of ~10%.</p> <p>The Company through its wholly owned subsidiary Alivira Animal Health Limited, Ireland currently holds 60% stake in Provet which was acquired in the year 2014.</p> <p>FY 2019-20 Consolidated Financials:</p> <p>Sales: ₹ 1351 Mn EBIDTA: ₹ 408 Mn Net Profit: ₹ 209 Mn</p>
2.	Whether the acquisition of the Target entity falls within the related party Transaction and whether the promoter/ promoter group/group companies have any interest in the entity being acquired	No
3.	Industry to which Target entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition	The object of acquisition is to consolidate the shareholding in Provet. Consequent to this acquisition, Provet will become a wholly owned subsidiary of the Company.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No
6.	Indicative time period for completion	On or before October 31, 2020
7.	Nature of consideration	Cash transaction

Krishab



8.	Percentage of shareholding/ control acquired and/ or number of shares acquired	The Company will acquire 40% stake in Provet through Alivira Animal Health Limited, Ireland, wholly owned subsidiary of the Company	
9.	Cost of acquisition or the price at which the shares are acquired	USD 1,71,02,658 Mn	
10.			
a.	Products/line of business acquired	<p>Brief Background:</p> <p>Provet has manufacturing facilities located at Polatli Industrial Zone, Ankara, Turkey. The Ankara facility is EUGMP and Turkish GMP approved with 8 different manufacturing lines. Provet operates in various dosage forms mainly dominated by injectables (solutions / suspensions), oral solutions, pour-on / spot-on, aerosols and intrauterine. There are more than 120 product registrations. The top products (in terms of revenues) are: -</p> <ul style="list-style-type: none"> • Blotic • Rabenzole • Amoxycure • Penstrep <p>The products mainly cater to the therapeutics such as Antibacterial, Ectop Parasite, Metabolic, Anthelmintic, Antiparasitic, Nutritional, etc.</p> <p>The products mostly cater to the ruminant species such as Cattle and Sheep.</p> <p>Line of Business: Pharmaceuticals</p>	
b.	Date of incorporation	08/02/1995	
c.	History of last 3 years Consolidated turnover (₹ in millions)	FY 2019-20	1,351
		FY 2018-19	914
		FY 2017-18	1,084
d.	Country in which the acquired entity has presence	Turkey	

Krishab

